← Volver a la portada
Estados Unidos · Plataformas y datos · The Motley Fool

2 Growth Stocks to Buy in November Without Any Hesitation

Publicado por The Motley Fool · Estados Unidos hace 1 h
2 Growth Stocks to Buy in November Without Any Hesitation
2 Growth Stocks to Buy in November Without Any Hesitation · The Motley Fool

Resumen detallado

Vertex and Regeneron started 2026 slowly, but blockbuster results and deep pipelines have both stocks climbing again.

Vertex Pharmaceuticals (VRTX -1.91%) and Regeneron (REGN -0.81%) did not have a strong start to the year -- both biotech giants were in decline for much of the first half of 2026. However, they have rebounded, and as of this writing, both have delivered above-average returns this year. They haven't peaked yet: Vertex Pharmaceuticals and Regeneron arguably remain excellent stocks to buy this month and hold onto over the medium term. Let me explain.

Vertex Pharmaceuticals could soon receive approval for a brand-new product, povetacicept. This investigational medicine for IgA nephropathy (a kidney disease) performed well in a Phase 3 study earlier this year, and regulators in the U.S. are expected to decide whether to approve it or not by the end of November. Povetacicept would be a nice addition to Vertex's lineup, which is still dominated by its cystic fibrosis (CF) medicines.

The drugmaker derives most of its revenue from CF therapies, an area where it is the undisputed leader. In the third quarter, Vertex's total revenue increased by 12% year over year to $3.44 billion. Vertex is unlikely to face stiff competition, generic or otherwise, within its core CF market anytime soon. But newer medicines, like povetacicept, will help expand and diversify its lineup.

Povetacicept could be the first of several drugs across kidney diseases for which Vertex earns approval. The company's pipeline also includes inaxaplin, an investigational medicine for APOL1-mediated kidney disease that is currently undergoing late-stage studies. Then there is VX-407, which is being developed to treat autosomal dominant polycystic kidney disease; VX-407 is in Phase 2 studies. Between them, these three drugs could eventually generate over $10 billion in peak annual sales, according to some estimates, which isn't that far off from the annual revenue it currently makes from its CF franchise.

Further, Vertex recently expanded its lineup and pipeline through the $10 billion acquisition of Crinetics…

Regen…

Inicio del artículo, extracto de The Motley Fool. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en The Motley Fool Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)

También te puede interesar